Denali Therapeutics’ $400 Million At-The-Market Offering

Davis Polk advised the sales agents in the transaction.The transaction consists in a new SEC-registered at-the-market offering program by Denali Therapeutics Inc. under which Denali may…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now